Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563669365> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2563669365 endingPage "4470" @default.
- W2563669365 startingPage "4470" @default.
- W2563669365 abstract "Abstract Abstract 4470 Chronic Myeloid Leukaemia (CML) is a malignant disorder of the haematopoeitic stem cell, usually characterised by the t(9;22) giving rise to the Philadelphia chromosome (Ph), and by the BCR-ABL gene rearrangement at the molecular level. Imatinib mesylate (IM), which targets the tyrosine kinase (TK) activity of BCR-ABL, has become the first line therapy for CML patients. Dasatinib or Nilotinib is now indicated as a second line therapy for patients who develop resistance or intolerance to IM. Here we report the case of a 51 year old woman who was diagnosed in Cyprus (2007) with BCR/ABL1 positive CML. After failing to respond to IM therapy, she was treated with Dasatinib achieving complete cytogenetic remission (CCR), and subsequent complete molecular remission. In July 2009 the patient presented with 88% blasts in the bone marrow. Immunophenotyping showed the presence of CD34+, CD117+ myeloblasts, and a diagnosis of AML was confirmed. Analysis of G banded metaphases from cultured peripheral blood revealed a complex karyotype: 46,XX, t(2;3)(p21;q26),t(4;8)(q12;q22), del(6)(q13;q23)[1]/45,idem,der(6)ins(6;6)(q23;),-7[9]. FISH revealed EVI 1 rearrangement resulting from the t(2;3) in the absence of BCR/ABL1 fusion and confirmed the secondary monosomy 7. The patients failed to respond to treatment and passed away shortly afterwards. Whole genome screening by aCGH using a 244K platform (Agilent) confirmed the loss of chromosome 7 and the 6q22/23 region. Clonal cytogenetic abnormalities (CCA) in Ph-negative metaphases are known to develop in some patients during IM therapy. The most frequent of these abnormalities are trisomy 8, -7, del(7q), and del(20q), which are also associated with MDS and AML. These abnormalities are usually transient and disappear after a short time, or have no clinical consequence (Deininger et al., Cancer 2007). However, reports of development of high risk MDS or AML in association with CCA in Ph-negative cells are rare, but patients with chromosome 7 abnormalities appear to be at greater risk. The t(2;3) is a non random abnormality in MDS and AML, including therapy-related leukaemias, frequently associated with -7 and a complex karyotype with a poor prognosis (Stevens-Kroef et al Leukemia 2004). This is the first report of a CML patient on TKI treatment with t(2;3) and EVI1 gene rearrangements in Ph(-) cells. This cryptic translocation could easily be overlooked in the presence of a monosomy 7 with a dramatic effect on patient management. Disclosures: No relevant conflicts of interest to declare." @default.
- W2563669365 created "2017-01-06" @default.
- W2563669365 creator A5017315111 @default.
- W2563669365 creator A5028883400 @default.
- W2563669365 creator A5029101558 @default.
- W2563669365 creator A5037232497 @default.
- W2563669365 creator A5077181013 @default.
- W2563669365 date "2010-11-19" @default.
- W2563669365 modified "2023-09-30" @default.
- W2563669365 title "A Cell Line SYRMO Derived From AML with EVI 1 Rearrangements Following Imatinib Mesylate Therapy for Chronic Myeloid Leukaemia" @default.
- W2563669365 doi "https://doi.org/10.1182/blood.v116.21.4470.4470" @default.
- W2563669365 hasPublicationYear "2010" @default.
- W2563669365 type Work @default.
- W2563669365 sameAs 2563669365 @default.
- W2563669365 citedByCount "0" @default.
- W2563669365 crossrefType "journal-article" @default.
- W2563669365 hasAuthorship W2563669365A5017315111 @default.
- W2563669365 hasAuthorship W2563669365A5028883400 @default.
- W2563669365 hasAuthorship W2563669365A5029101558 @default.
- W2563669365 hasAuthorship W2563669365A5037232497 @default.
- W2563669365 hasAuthorship W2563669365A5077181013 @default.
- W2563669365 hasConcept C10205521 @default.
- W2563669365 hasConcept C104317684 @default.
- W2563669365 hasConcept C126322002 @default.
- W2563669365 hasConcept C138626823 @default.
- W2563669365 hasConcept C143998085 @default.
- W2563669365 hasConcept C196166836 @default.
- W2563669365 hasConcept C203014093 @default.
- W2563669365 hasConcept C2776839831 @default.
- W2563669365 hasConcept C2777413986 @default.
- W2563669365 hasConcept C2777583451 @default.
- W2563669365 hasConcept C2778729363 @default.
- W2563669365 hasConcept C2778904597 @default.
- W2563669365 hasConcept C2779536868 @default.
- W2563669365 hasConcept C2780365373 @default.
- W2563669365 hasConcept C28328180 @default.
- W2563669365 hasConcept C3019892230 @default.
- W2563669365 hasConcept C30481170 @default.
- W2563669365 hasConcept C502942594 @default.
- W2563669365 hasConcept C53226629 @default.
- W2563669365 hasConcept C54355233 @default.
- W2563669365 hasConcept C553184892 @default.
- W2563669365 hasConcept C71924100 @default.
- W2563669365 hasConcept C86803240 @default.
- W2563669365 hasConceptScore W2563669365C10205521 @default.
- W2563669365 hasConceptScore W2563669365C104317684 @default.
- W2563669365 hasConceptScore W2563669365C126322002 @default.
- W2563669365 hasConceptScore W2563669365C138626823 @default.
- W2563669365 hasConceptScore W2563669365C143998085 @default.
- W2563669365 hasConceptScore W2563669365C196166836 @default.
- W2563669365 hasConceptScore W2563669365C203014093 @default.
- W2563669365 hasConceptScore W2563669365C2776839831 @default.
- W2563669365 hasConceptScore W2563669365C2777413986 @default.
- W2563669365 hasConceptScore W2563669365C2777583451 @default.
- W2563669365 hasConceptScore W2563669365C2778729363 @default.
- W2563669365 hasConceptScore W2563669365C2778904597 @default.
- W2563669365 hasConceptScore W2563669365C2779536868 @default.
- W2563669365 hasConceptScore W2563669365C2780365373 @default.
- W2563669365 hasConceptScore W2563669365C28328180 @default.
- W2563669365 hasConceptScore W2563669365C3019892230 @default.
- W2563669365 hasConceptScore W2563669365C30481170 @default.
- W2563669365 hasConceptScore W2563669365C502942594 @default.
- W2563669365 hasConceptScore W2563669365C53226629 @default.
- W2563669365 hasConceptScore W2563669365C54355233 @default.
- W2563669365 hasConceptScore W2563669365C553184892 @default.
- W2563669365 hasConceptScore W2563669365C71924100 @default.
- W2563669365 hasConceptScore W2563669365C86803240 @default.
- W2563669365 hasIssue "21" @default.
- W2563669365 hasLocation W25636693651 @default.
- W2563669365 hasOpenAccess W2563669365 @default.
- W2563669365 hasPrimaryLocation W25636693651 @default.
- W2563669365 hasRelatedWork W1554937972 @default.
- W2563669365 hasRelatedWork W17970610 @default.
- W2563669365 hasRelatedWork W2025935458 @default.
- W2563669365 hasRelatedWork W2053212028 @default.
- W2563669365 hasRelatedWork W2120868842 @default.
- W2563669365 hasRelatedWork W2155107050 @default.
- W2563669365 hasRelatedWork W2306349432 @default.
- W2563669365 hasRelatedWork W2563669365 @default.
- W2563669365 hasRelatedWork W3143018572 @default.
- W2563669365 hasRelatedWork W3206268020 @default.
- W2563669365 hasVolume "116" @default.
- W2563669365 isParatext "false" @default.
- W2563669365 isRetracted "false" @default.
- W2563669365 magId "2563669365" @default.
- W2563669365 workType "article" @default.